AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
A Phase I Investigation of the Intravenous Administration of AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
  • Phase

    Phase 1
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    ags-1c4d4 ...
  • Study Participants

The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of AGS-1C4D4 in patients with advanced HRPC.
Cohorts of 1-6 patients will be administered AGS-1C404 in sequentially rising dose levels. Dose escalation will continue until the MTD of AGS-1C4D4 is established or the maximum planned dose is reached.
Study Started
Sep 30
Primary Completion
Sep 30
Study Completion
Sep 30
Last Update
May 02

Drug AGS-1C4D4


1.AGS-1C4D4 Experimental


Inclusion Criteria:

Patient has hormone-refractory metastatic prostate cancer

Exclusion Criteria:

Patient has had chemotherapy, radiotherapy, or biological therapy within the past 4 weeks or has not recovered from side effects
Patient is currently participating or has participated in an investigational study within the past 30 days
Patient has illness or circumstance that could limit compliance with the study requirements
Patient uses illicit drugs or had a recent history of drug or alcohol abuse within the last year
Patient has Hepatitis B or C
No Results Posted